Press Releases
December 21, 2023
Panbela Announces Exercise of Warrants, Issuance of New Warrants in Private Placement for $2M Gross Proceeds Priced At-the-Market
December 18, 2023
Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
December 4, 2023
Panbela Announces Publication of Abstract: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors
November 29, 2023
Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
November 9, 2023
Panbela Provides Business Update and Reports Q3 2023 Financial Results
November 3, 2023
Panbela Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9M Gross Proceeds Priced At-the-Market
November 2, 2023
Panbela Announces Publication of Preclinical and Clinical Data: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
A Phase 1 clinical study showed that DFMO treatment may provide metabolic benefits to preserve β cell function and health in T1D.
October 31, 2023
Panbela Announces Validation of European Patent for Claims of a Novel Process for the Production of SBP-101
October 25, 2023
Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
October 24, 2023